M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal BioSpaceOf the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb.OncologyRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionNext: Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
